RA Capital Management, L.P. 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 4,724,352 9.990% | 870,485 (+22.59%) | Filing |
| 2023-02-14 4:45 pm Purchase | 2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 3,853,867 8.900% | 668,036 (+20.97%) | Filing |
| 2022-10-17 5:21 pm Purchase | 2022-10-07 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 3,185,831 8.160% | 3,185,831 (New Position) | Filing |
| 2021-05-17 4:33 pm Sale | 2021-05-17 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 0 0.000% | -2,129,003 (Position Closed) | Filing |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA Capital Management, L.P. | 2,129,003 5.600% | 2,129,003 (New Position) | Filing |